Glasdegib: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
G-BA (Germany) recommended or restricted glasdegib, while CIPM (Spain) did not recommend it.
The record spans 2.9 years, opening at NICE (England) on 2 Sep 2020 and running to 27 Aug 2023.
No assessment is on file from HAS (France), PBAC (Australia), PHARMAC (New Zealand) and TLV (Sweden), each among the eight highest-volume agencies here.
Not every gap is a refusal: for glasdegib, 1 submission was never made and 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
3 distinct indication wordings are recorded for glasdegib by the agencies that label one in English (AWMSG, NICE and SMC).
NICE (England) was first to assess glasdegib, on 2 Sep 2020; NYE METODER (Norway) did not open a file until 27 Aug 2023 — a moderate spread of 2.9 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 3 of 7 dated records fall in 2021 alone.
CIPM (Spain) is the only agency to have returned to glasdegib, recording 2 separate entries.
6 of the 18 agencies in this archive hold a record for glasdegib.
The full ledger for glasdegib reads 2 not recommended, 1 other, 1 recommended and 1 non-submission, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| NYE METODER (Norway) | 27 Aug 2023 | Til behandling av akutt myelogen leukemi (AML). | decision recorded | source |
| CIPM (Spain) | 4 Apr 2022 | Indicaciones terapéuticas autorizadas: Daurismo está indicado, en combinación con dosis bajas de citarabina, para el tra… | not financed by the SNS · art. 92 d, e | source |
| G-BA (Germany) | 18 Feb 2021 | Daurismo — benefit assessment §35a | added benefit: considerable (hint) | source |
| SMC (Scotland) | 8 Feb 2021 | In combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (AML) in adult patients who are not candidates … | not recommended | source |
| NICE (England) | 2 Sep 2020 | NICE TA646 | terminated appraisal | source |
2 further decisions for glasdegib, across 2 agencies, are not shown here. They link to 2 further source documents.
Related molecules
- venetoclax — divergent outcome (not recommended vs recommended) on a shared indication
- atezolizumab — same ATC class L01X — Antineoplastics
- olaparib — same ATC class L01X — Antineoplastics
- durvalumab — same ATC class L01X — Antineoplastics
- aflibercept — same ATC class L01X — Antineoplastics
- osimertinib — same ATC class L01X — Antineoplastics
Coverage: 7 decisions for glasdegib from 6 agencies, 2020 to 2023. Data to 7 Sep 2026. ATC class L01X — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.